Submit NDA for relacorilant in platinum-resistant ovarian cancer
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 5 May 2025
- Due
- 30 Sep 2025
- Delivered
- July 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“We will submit our NDA next quarter for relacorilant in platinum-resistant ovarian cancer.”
What we found
Evidence strength A What the grades mean
The company successfully submitted the NDA for relacorilant in platinum-resistant ovarian cancer in July 2025, which falls within the third quarter of 2025.
-
A Corcept Therapeutics Inc. 10-Q filed 2025-11-04
“In July 2025, we submitted an NDA seeking approval to market relacorilant plus the chemotherapy medication nab-paclitaxel as a treatment for patients with platinum-resistant ovarian cancer in the United States.” ✓ confirmed on the page
Market reaction: the shares moved +0.4% against the S&P 500 over the three sessions around the disclosure (3 Nov 2025 to 6 Nov 2025). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory submission
- Indicative materiality
- High rules
- Action
- Submit
- Deliverable
- NDA for relacorilant
- Language
- Firm (“will”, “on track to”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Corcept Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-CORT-002912 · Corrections policy